AstraZeneca PLC
AZN89.830USD
-0.460-0.51%
Fechamento 12/12, 16:00（ET）Cotações atrasadas em 15 min
278.60BValor de mercado
29.63P/L TTM
Mais detalhes de AstraZeneca PLC Empresa
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
Informações de AstraZeneca PLC
Código da empresaAZN
Nome da EmpresaAstraZeneca PLC
Data de listagemSep 21, 2007
CEODunoyer (Marc)
Número de funcionários94300
Tipo de títulosDepository Receipt
Fim do ano fiscalSep 21
Endereço1 Francis Crick Avenue
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalCB2 0AA
Telefone442073045000
Sitehttps://www.astrazeneca.com/
Código da empresaAZN
Data de listagemSep 21, 2007
CEODunoyer (Marc)
Executivos da empresa AstraZeneca PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Aradhana Sarin, M.D.
Ms. Aradhana Sarin, M.D.
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
Outro
6.33B
45.89%
Por RegiãoUSD
Nome
Receita
Proporção
United States
6.32B
45.84%
Europe
3.07B
22.23%
EX-China
2.04B
14.82%
China
1.71B
12.40%
Established ROW
1.31B
9.53%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Farxiga
2.15B
15.59%
Tagrisso
1.81B
13.12%
Imfinzi
1.46B
10.55%
Ultomiris
1.18B
8.53%
Calquenc
872.00M
6.32%
Outro
6.33B
45.89%
Distribuição de ações
Atualizado em: ter, 25 de nov
Atualizado em: ter, 25 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
Outro
95.15%
Investidores
Investidores
Proporção
PRIMECAP Management Company
1.29%
Wellington Management Company, LLP
1.04%
T. Rowe Price International Ltd
1.00%
Capital International Investors
0.81%
Managed Account Advisors LLC
0.72%
Outro
95.15%
Tipos de investidores
Investidores
Proporção
Investment Advisor
8.78%
Investment Advisor/Hedge Fund
5.84%
Research Firm
1.11%
Hedge Fund
0.69%
Bank and Trust
0.19%
Pension Fund
0.06%
Venture Capital
0.03%
Family Office
0.02%
Family Office
0.02%
Outro
83.27%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
2038
518.15M
17.29%
+1.97M
2025Q3
2089
516.24M
17.34%
-2.62M
2025Q2
2062
519.46M
17.59%
-9.37M
2025Q1
2054
529.82M
17.91%
-25.96M
2024Q4
2001
537.38M
17.35%
+13.04M
2024Q3
1925
524.26M
17.32%
+244.85K
2024Q2
1912
524.03M
17.41%
+1.94M
2024Q1
1863
521.64M
17.31%
-15.18M
2023Q4
1837
514.30M
17.42%
-5.99M
2023Q3
1809
522.19M
17.30%
+4.27M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
PRIMECAP Management Company
41.20M
1.33%
+538.61K
+1.32%
Jun 30, 2025
Wellington Management Company, LLP
34.34M
1.11%
-1.29M
-3.63%
Jun 30, 2025
T. Rowe Price International Ltd
30.71M
0.99%
+3.43M
+12.56%
Jun 30, 2025
Capital International Investors
31.40M
1.01%
+119.42K
+0.38%
Jun 30, 2025
Managed Account Advisors LLC
21.15M
0.68%
-1.37M
-6.07%
Jun 30, 2025
Fisher Investments
20.70M
0.67%
+530.52K
+2.63%
Jun 30, 2025
Fidelity Management & Research Company LLC
18.04M
0.58%
-944.35K
-4.97%
Jun 30, 2025
T. Rowe Price Associates, Inc.
21.24M
0.68%
-8.57M
-28.75%
Jun 30, 2025
Sanders Capital, LLC
14.53M
0.47%
-542.12K
-3.60%
Jun 30, 2025
Putnam Investment Management, L.L.C.
12.48M
0.4%
+184.41K
+1.50%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Nome
Proporção
Amplify Weight Loss Drug & Treatment ETF
5.58%
VanEck Pharmaceutical ETF
4.97%
Invesco Nasdaq Biotechnology ETF
4.81%
ProShares Ultra Nasdaq Biotechnology
4.81%
Parnassus Value Select ETF
4.66%
Invesco QQQ Low Volatility ETF
4.19%
Roundhill GLP-1 & Weight Loss ETF
3.36%
Abacus FCF International Leaders ETF
3.28%
Global X Aging Population ETF
3.2%
Franklin Genomic Advancements ETF
3.05%
Ver Mais
Amplify Weight Loss Drug & Treatment ETF
Proporção5.58%
VanEck Pharmaceutical ETF
Proporção4.97%
Invesco Nasdaq Biotechnology ETF
Proporção4.81%
ProShares Ultra Nasdaq Biotechnology
Proporção4.81%
Parnassus Value Select ETF
Proporção4.66%
Invesco QQQ Low Volatility ETF
Proporção4.19%
Roundhill GLP-1 & Weight Loss ETF
Proporção3.36%
Abacus FCF International Leaders ETF
Proporção3.28%
Global X Aging Population ETF
Proporção3.2%
Franklin Genomic Advancements ETF
Proporção3.05%
Dividendo
Um total de
20.90B
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Jul 29, 2025
AZN.NB Final Cash Dividend of gross USD 0.515 paid on Sep 08, 2025 going ex on Aug 08, 2025
Aug 08, 2025
Sep 08, 2025
Aug 08, 2025
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de AstraZeneca PLC?
Os cinco principais acionistas de AstraZeneca PLC são:
PRIMECAP Management Company detém 41.20M Ações, representando 1.33% do total de Ações.
Wellington Management Company, LLP detém 34.34M Ações, representando 1.11% do total de Ações.
T. Rowe Price International Ltd detém 30.71M Ações, representando 0.99% do total de Ações.
Capital International Investors detém 31.40M Ações, representando 1.01% do total de Ações.
Managed Account Advisors LLC detém 21.15M Ações, representando 0.68% do total de Ações.
PRIMECAP Management Company detém 41.20M Ações, representando 1.33% do total de Ações.
Wellington Management Company, LLP detém 34.34M Ações, representando 1.11% do total de Ações.
T. Rowe Price International Ltd detém 30.71M Ações, representando 0.99% do total de Ações.
Capital International Investors detém 31.40M Ações, representando 1.01% do total de Ações.
Managed Account Advisors LLC detém 21.15M Ações, representando 0.68% do total de Ações.
Quais são os três principais tipos de acionistas de AstraZeneca PLC?
Os três principais tipos de acionistas da AstraZeneca PLC são:
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
PRIMECAP Management Company
Wellington Management Company, LLP
T. Rowe Price International Ltd
Quantas instituições possuem ações da AstraZeneca PLC (AZN)?
Em 2025Q4, 2038 instituições possuíam ações da AstraZeneca PLC, com valor de mercado aproximado de 518.15M, representando 17.29% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em -0.05%.
Qual é a maior fonte de receita da AstraZeneca PLC?
Em FY2025Q2, o segmento de negócios Farxiga gerou a maior receita para AstraZeneca PLC, totalizando 2.15B e representando 15.59% da receita total.
